UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 152

Sortiert nach

Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

Journal of clinical oncology, 2009-08, Vol.27 (24), p.3994-4001

2009

Link zum Volltext

Verfügbarkeit prüfen

Weniger Zyklen, gleiche Effektivität?

InFo Hämatologie + Onkologie, 2020-03, Vol.23 (3), p.32-34

Hensel, Manfred

2020

Link zum Volltext

Verfügbarkeit prüfen

Health status and infections in patients with symptomatic primary and secondary immunoglobulin G (IgG) deficiencies receiving intravenous IgG replacement

BMC immunology, 2020-06, Vol.21 (1), p.1-39, Article 39

2020

Link zum Volltext

Verfügbarkeit prüfen

Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial

BMC cancer, 2011-02, Vol.11 (1), p.87-87, Article 87

2011

Link zum Volltext

Verfügbarkeit prüfen

Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry

Therapeutic advances in neurological disorders, 2016-05, Vol.9 (3), p.165-179

2016

Link zum Volltext

Verfügbarkeit prüfen

JAK2 -V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia

The lancet oncology, 2007-07, Vol.8 (7), p.658-660

2007

Link zum Volltext

Verfügbarkeit prüfen

The bcl-2/IgH rearrangement in a population of 204 healthy individuals: Occurrence, age and gender distribution, breakpoints, and detection method validity

Leukemia research, 2006-06, Vol.30 (6), p.745-750

2006

Link zum Volltext

Verfügbarkeit prüfen

Drug Interactions in the Treatment of Malignancy in HIV-Infected Patients

Oncology research and treatment, 2017, Vol.40 (3), p.120-127

2017

Link zum Volltext

Verfügbarkeit prüfen

High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany

Supportive care in cancer, 2019-11, Vol.27 (11), p.4265-4271

2019

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

The lancet oncology, 2018-11, Vol.19 (11), p.1530-1542

2018

Link zum Volltext

Verfügbarkeit prüfen

Drug-perturbation-based stratification of blood cancer

The Journal of clinical investigation, 2018-01, Vol.128 (1), p.427-445

2018

Link zum Volltext

Verfügbarkeit prüfen

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

Blood, 2006-02, Vol.107 (3), p.885-891

2006

Link zum Volltext

Verfügbarkeit prüfen

Response to the letter to the Editor concerning our article “High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany”

Supportive care in cancer, 2020, Vol.28 (1), p.3-4

2020

Link zum Volltext

Verfügbarkeit prüfen

2022-RA-837-ESGO Characterization of long-term survivor and maintenance therapy in relapsed ovarian cancer (CAROLIN)- Intergroup study NOGGO/A-AGO

International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A269-A269

2022

Link zum Volltext

Verfügbarkeit prüfen

Therapy of HIV-associated lymphoma—recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG)

Annals of hematology, 2014-06, Vol.93 (6), p.913-921

2014

Link zum Volltext

Verfügbarkeit prüfen

Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long‐term data of the SIGNS study

European journal of haematology, 2017-08, Vol.99 (2), p.169-177

2017

Link zum Volltext

Verfügbarkeit prüfen

SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues

Leukemia research, 2021-08, Vol.107, p.106608-106608, Article 106608

2021

Link zum Volltext

Verfügbarkeit prüfen

Rituximab maintenance improves survival in male patients with diffuse large B‐cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial

British journal of haematology, 2015-12, Vol.171 (5), p.710-719

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 152

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(132)
Mit Volltextzugriff
(141)

Publikationsform

Sprache

Englisch
(137)
Deutsch
(14)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(71)
Life Sciences & Biomedicine
(66)
Humans
(57)
Middle Aged
(40)
Male
(39)
Female
(38)
Hematology
(36)
Aged
(34)
Adult
(33)
Oncology
(33)
Rituximab
(17)
Biological And Medical Sciences
(15)
Medical Sciences
(15)
Treatment Outcome
(15)
Aged, 80 And Over
(13)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(12)
Hematologic And Hematopoietic Diseases
(12)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(12)
Prospective Studies
(12)
Antibodies, Monoclonal, Murine-Derived
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

Weniger Zyklen, gleiche Effektivität?

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

Health status and infections in patients with symptomatic primary and secondary immunoglobulin G (IgG) deficiencies receiving intravenous IgG replacement

Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial

Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry

JAK2 -V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia

The bcl-2/IgH rearrangement in a population of 204 healthy individuals: Occurrence, age and gender distribution, breakpoints, and detection method validity

Drug Interactions in the Treatment of Malignancy in HIV-Infected Patients

High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Drug-perturbation-based stratification of blood cancer

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B

Response to the letter to the Editor concerning our article “High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany”

2022-RA-837-ESGO Characterization of long-term survivor and maintenance therapy in relapsed ovarian cancer (CAROLIN)- Intergroup study NOGGO/A-AGO

Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial

Therapy of HIV-associated lymphoma—recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG)

Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long‐term data of the SIGNS study

SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues

Rituximab maintenance improves survival in male patients with diffuse large B‐cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial

Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy

Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial

Suchergebnisse filtern